Couverture de Medical News Podcast

Medical News Podcast

Medical News Podcast

De : PeerDirect
Écouter gratuitement

À propos de ce contenu audio

 The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.Copyright © 2024 PeerDirect Publishing Hygiène et vie saine Maladie et pathologies physiques Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

      HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025
      Feb 18 2026
      Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.
      Afficher plus Afficher moins
      13 min
    • HER2+ Endometrial and Ovarian Cancers

      HER2+ Endometrial and Ovarian Cancers
      Feb 17 2026
      Drs. Campos and Dizon explore how groundbreaking research is redefining HER2-targeted therapies in gynecological cancers, moving beyond the old one-size-fits-all approach. They spotlight the promise and ongoing challenges of customizing treatment using new biomarkers and clinical trial data.
      Afficher plus Afficher moins
      13 min
    • Can an oral PCSK9 inhibitor finally close the LDL gap for high-risk patients?

      Can an oral PCSK9 inhibitor finally close the LDL gap for high-risk patients?
      Feb 13 2026
      A phase 3 trial in The New England Journal of Medicine found that the oral PCSK9 inhibitor enlicitide reduced LDL by 57% at 24 weeks in high-risk patients, with similar adverse events to placebo. An oral option may improve uptake and help more patients reach lipid targets. In The Lancet, SMART-CHOICE 3 showed clopidogrel monotherapy after DAPT post-PCI reduced death, MI, or stroke versus aspirin, without more bleeding. Finally, a large meta-analysis confirmed most reported statin side effects are not causally linked, reinforcing their strong benefit–risk profile.
      Afficher plus Afficher moins
      5 min
    Aucun commentaire pour le moment